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Introduction
Attention deficit hyperactivity disorder (ADHD) is characterized by a clinical phenotype of hyperactivity, impulsivity and inattention [1] , and is among the most common neuropsychiatric disorders in childhood, affecting from 3 to 7% of school-aged children [2, 3] . The symptoms of ADHD in children typically developed during their preschool years [4] . Moreover, ADHD children tend to undergo social and emotional problems that cause academic difficulties and antisocial behaviors [5] . Therefore, early identification and treatment are important to improving the quality of life of ADHD patients [6] .
The American Academy of Pediatrics (AAP) has recommended both medication and nonmedication (e.g. behavioral and/or community) treatments for ADHD children. For school-aged children, a considerable amount of evidence provides support for the recommendation of the administration of psychostimulants, such as methylphenidate (MPH), as the first-choice treatment [7, 8] . MPH has been reported as the most effective treatment, improving attention and behavior as well as cognition and social function [9] in 70% of patients [10, 11] . MPH inhibits the reuptake of catecholamines, especially dopamine, by blocking their transporters, and consequently acts as a dopamine inducer in the cerebral cortices and striatal regions [12] . The effect of MPH as a dopamine inducer makes it a reasonable treatment for ADHD from a genetic perspective as ADHD is thought to be associated with several dopamine-related genes, including the catechol-O-methyltransferase (COMT) gene [13] , the dopamine receptor D4 (DRD4) gene and the dopamine active transporter 1 gene (DAT1, also known as SLC6A3) [14] at the prefrontal cortex in ADHD.
To diagnose ADHD and evaluate treatment, clinicians usually refer to the severity levels of symptoms listed on rating questionnaires for subjective measures of ADHD symptoms, including the ADHD Rating Scale and the Clinical Global Impression-Improvement of Illness scale [15] . However, the rating of symptoms is usually conducted by children's parents or teachers, and tends, unfortunately, to be subjective. Therefore, more objective approaches are urgently required [16] . In addition, more than four weeks of investigation is necessary to assess whether a patient is a responder or a non-responder to MPH [15] . Since MPH treatment has side effects such as appetite loss, tics, insomnia and stomachaches [17] , discrimination between responders and non-responders should be done as quickly as possible. However, an objective biomarker for its pharmacological effect has yet to be established. Therefore, in order to ensure successful early diagnosis and treatment with medication of ADHD children, it is important to establish an objective biomarker to assess the effectiveness of MPH as early as possible after its initiation in medication-naïve ADHD children.
The use of noninvasive functional neuroimaging methods, such as functional magnetic resonance imaging (fMRI), single photon
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Medication-naïve ADHD children without ASD exhibited reduced right prefrontal activation. MPH medication elicited significant right prefrontal activation except in comparative conditions associated with the placebo effect. Medication-naïve ADHD children with ASD exhibited marginal activation before the first day of medication and reduced activation after MPH medication in the right prefrontal area. While the neuropharmacological effects of MPH were different, ADHD-RS-IV-J scores were significantly improved one month after MPH administration in ADHD groups both with and without ASD.
Methylphenidate-Elicited Distinct Neuropharmacological Activation Patterns Between Medication-Naïve Attention Deficit Hyperactivity Disorder Children With and Without Comorbid Autism Spectrum Disorder: A Functional Near-Infrared Spectroscopy Study emission computed tomography (SPECT), positron emission tomography (PET), and, lately, functional near-infrared spectroscopy (fNIRS), is one potential approach to detecting candidate biomarkers for ADHD. Among these neuroimaging modalities, fNIRS offers several advantages such as its usefulness in an ordinary examination room, accessibility and tolerance to body motion [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , and, thus, is suitable for the objective diagnosis of ADHD children and for assessing their treatment. Since the 2000s, fMRI research has examined pharmacological effects in ADHD from the perspective of brain function [29] [30] [31] . In general, these studies have revealed that the blood-oxygenation-leveldependent signal within the prefrontal cortex (PFC) is related to administration of ADHD therapeutic agents. However, because of the high elimination rate of fMRI measurement, amounting to the rejection of 50% of ADHD children due to excessive motion artifacts [32] , the efficacy of fMRI may be limited for clinical applications.
However, research into the clinical application of fNIRS to monitor the effects of neurostimulants on cortical hemodynamic changes is currently being undertaken. Thus far, to our knowledge, there have been eleven reports on fNIRS-based exploration of neuropharmacological assessment of ADHD children since 2011 [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [42] . All of the studies described above included children with ADHD aged 6-16 years as subjects.
Meanwhile, in search of a stable biological marker, we have thus far explored the utility of the fNIRS monitoring method as a clinical tool for early diagnosis and treatment of ADHD children. Specifically, we applied an fNIRS-based clinically oriented evaluation method with young ADHD children, and accumulated evidence of neuro-functional modulation of the right inferior and middle frontal gyri (IFG/MFG), which is critical in inhibitory function, induced by MPH [40] . Subsequently, we examined the pharmacological effects of MPH [40] and ATX [38] in a randomized, double-blind, placebocontrolled, crossover study, revealing that both medications modulated hemodynamic responses in the right IFG/MFG during a go/no-go task while a placebo did not. Similar hemodynamic modulations after both medications were also observed when an oddball task was adopted [36, 37] .
Furthermore, fNIRS has successfully allowed visualization of the differential neural substrate between ADHD and healthy control children in inhibitory [38, 40, 43] and attentional [34, 35] tasks with group analyses. While a go/no-go task recruits the right IFG/MFG in control children, this activation is absent in ADHD children. These findings led us to postulate that the right IFG/MFG activations as observed using fNIRS, especially for go/no-go tasks, would serve as an objective neuro-functional biomarker to diagnose school-aged ADHD children, possibly even at the individual level.
Subsequently, we succeeded in individually differentiating ADHD children from typicallydeveloping control children using multichannel fNIRS with an area under a receiver operating characteristic (ROC) curve value of 90% and with sensitivity and specificity over 70%. This is promising efficacy for individual diagnosis of ADHD children [44] . These findings led us to conclude that the activation in the IFG/MFG could serve as an objective neuro-functional biomarker associated with a specific core neuropathological mechanism for inhibitory control in ADHD children. However, in order to open up our fNIRS measurement tool as the template method for the objective clinical diagnosis and treatment of ADHD children, we must consider an important issue: the complication of autism spectrum disorder (ASD).
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In our 2012 study (see Figure 4 on clinical neurophysiology in [40] ), we reported preliminary findings for unique, MPH-elicited neuropharmacological activation between ADHD with and without comorbid ASD; although the association between a go/no-go paradigm and right IFG/MFG activation as a biological marker is expected to be stable in ADHD without ASD, this may not be the case for ADHD with ASD.
Until 2012, the DSM-IV ADHD diagnostic criteria had specified that an ASD diagnosis was an exclusion criterion for ADHD, which resulted in limited research of the common clinical comorbidity [14] . However, in 2013, the DSM-5, in its revised criteria, recognized the frequency of the occurrence of ADHD with ASD and allowed, for the first time, a comorbid diagnosis of ADHD with ASD [1, 14] . Indeed, an increasing number of clinical [45] and psychological [46] studies on the co-occurrence of ADHD and ASD have been published since 2013. Concerning pharmacological studies, the response rate for MPH has been reported as lower in ADHD with ASD than in ADHD alone [47] . In addition, while MPH may worsen irritability in ADHD with ASD, it appears to improve it in ADHD without ASD [47] .
Although ADHD with and without ASD may have important differences in core neurofunctional pathology, to date neurophysiological and neuroimaging evidence has only been presented in two pioneering studies that used electroencephalogram (EEG) [48] and fMRI [49] . The EEG study on eventrelated potentials (ERPs) during a continuous performance task demonstrated different ERP patterns between ADHD with ASD, ADHD without ASD and ASD without ADHD in 8-to 13-year-olds [48] . On the other hand, the fMRI study demonstrated that ADHD patients with ASD aged 11-17 years exhibited a greater association of a temporal discounting task with several brain regions, including the PFC, than did control and non-comorbid groups [49] . Therefore, a better understanding of the neuropharmacological endophenotype of the comorbidity of ADHD with ASD is important because it could provide clues for new treatment options as well as objective evidence for the existence of a distinct phenotype [46] . However, to our knowledge, no neuroimaging study has explored the differences in neuropharmacological effects between ADHD with ASD and ADHD without ASD. When this history and these results are taken together, it is clear that the time has come to explore the neuropathology of ADHD with and without comorbid ASD using fNIRS measurement. Hence, in the current study, we extended our previous fNIRS studies to include the assessment of medication-naïve ADHD children with and without comorbid ASD in order to examine the neuropharmacological effect of MPH on the cortical hemodynamics of ADHD during a go/no-go task. ADHD children received either MPH or a placebo according to a randomized, double-blind, placebo-controlled, crossover design. We hypothesized that MPH would modulate hemodynamic responses differently in ADHD children with ASD and ADHD children without ASD.
Materials and Methods
Participants and ethics
Thirty-two clinically referred medication-naïve, right-handed Japanese children, diagnosed as ADHD based on the DSM-5 by trained pediatric neurologists and requiring the administration of MPH, were randomly recruited at Jichi Medical University and the Rehabilitation Center of the In this study, we selected medication-naïve ADHD children. Although our previous studies included both medicated and medication-naïve patients, according to animal [50] and human anatomical studies [51] [52] [53] , brain function and structure can change with long-term MPH administration.
All participants and their parents gave oral consent to participation in the study. Written consent was obtained from the guardians of all subjects according to the latest version of the Declaration of Helsinki. The study was approved by the Ethics Committees of Jichi Medical University Hospital and the International University of Health and Welfare.
Experimental design
The effects of MPH were evaluated in a randomized, double-blind, placebo-controlled, crossover design, using MPH (18 mg). The participants visited either of the two hospitals twice, and were medicated with MPH during their first visit and a placebo during their second visit, or vice versa. Their order was allocated in a pseudo-randomized order to avoid order effects, and counter-balanced across all patients. In order to avoid patients' own biased expectations of the results, we adopted a double-blind design in which neither researchers nor patients knew whether a placebo or MPH was administered.
Cortical activation was measured with fNIRS during a go/no-go task. Experimental procedure was identical to .
In addition, to evaluate the pharmacological effect, a Japanese version of the ADHD Rating Scale-IV(ADHD-RS-IV-J) [54] was given before starting oral administration and 1 month after the current study. ADHD-RS-IV-J is an 18-item scale with each item corresponding to one of the 18 symptoms reflecting the DSM-IV diagnostic criteria for ADHD (American Psychiatric Association 1994; [55] ). The questionnaire was responded to by each patient's parents.
Experimental stimulus
We adopted the go/no-go task in a block design [25, [56] [57] [58] [59] . We presented four types of animal pictures on a computer screen using E-prime 2.0 (Psychology Software Tools). A go/no-go task consisted of six 2-block sets. Each set contained a go (baseline) block, where participants were randomly presented with two types of animal pictures and asked to respond to both pictures, and a go/no-go (target) block, where participants were randomly presented with a no-go picture 50% of the time and asked to respond to all the pictures except the no-go picture. Baseline and target blocks were alternated. Each block lasted for 24 s and was preceded by instructions for 3 s for a total session time of 6 min. For the go block, participants were instructed, "when you see each picture, you should press the space key as quickly as you can". For the go/no-go block, subjects were instructed, "when you see the no-go picture, you should not press the space key". Pictures were presented sequentially for 800 ms with an inter-stimulus interval of 200 ms during go and go/no-go blocks.
fNIRS measurement
We used the multichannel fNIRS system ETG-4000 (Hitachi Corporation, Tokyo, Japan), using two wavelengths of near-infrared light (695 and 830 nm). We analyzed the optical data based on the modified Beer-Lambert Law [60] as previously described [61] . Signals reflecting the oxygenated hemoglobin (oxy-Hb), deoxygenated hemoglobin (deoxy-Hb), and total hemoglobin (total-Hb) changes were calculated in units of millimolar·millimeter (mM·mm) [61, 62] . The sampling rate was set at 10Hz. We analyzed oxyHb signal as in previously described [40, 44] .
fNIRS probe placement
We set the fNIRS probes to cover IFG and MFG activation foci in reference to our previous studies [38, 40, 43, 44] . We used 2 sets of 3×5 multichannel probe holders, consisting of 8 illuminating and 7 detecting probes arranged alternately at an interprobe distance of 3 cm, resulting in 22 channels (CH) per set. The midpoint of a pair of illuminating and detecting probes was defined as a channel location. The bilateral probe holders were attached Research Yukifumi Monden in the following manner: (1) their upper anterior corners, where the left and right probe holders were connected by a belt, were symmetrically placed across the sagittal midline; (2) the lower anterior corners of the probe holder were placed over the supraorbital prominence; (3) the lower edges of the probe holders were attached to the upper part of the auricles (Figure 1 ).
For spatial profiling of fNIRS data, we adopted the probabilistic registration method [63] [64] [65] to register fNIRS data to Montreal Neurological Institute (MNI) standard brain space. Specifically, the positions for channels and reference points, which included the Nz (nasion), Cz (midline central) and left and right preauricular points, were measured using a threedimensional digitizer in real-world (RW) space. We affine-transformed each RW reference point to the corresponding MRI-database reference point and then replaced them to MNI space. Adopting the same transformation parameters enabled us to obtain the MNI coordinate values for the fNIRS channels in order to obtain the most likely estimate of the location of given channels for the group of participants, and the (Table 2) . Finally, the estimated locations were anatomically labeled using a MATLAB® function that reads anatomical labeling information coded in a microanatomical brain atlas, LBPA40 [66] and Brodmann's atlas [67] .
Analysis of fNIRS data
We preprocessed individual timeline data for the oxy-Hb signals of each channel with a first-degree polynominal fitting and high-pass filter using cutoff frequencies of 0.01 Hz to remove baseline drift, and a 0.8 Hz low-pass filter to remove heartbeat pulsations. From the preprocessed time series data, we computed channel-wise and participant-wise contrasts by calculating the inter-trial mean of differences between the oxy-Hb signals for target (4 s to end of task after go/no-go block onset) and baseline (14 to 24 s after go block onset) periods.
For the 6 go/no-go block sets, we removed the blocks with sudden, obvious, discontinuous noise based on independent visual examination by two raters. Cohen's Kappa coefficient for inter-rater consistency was 1.00. Furthermore, we excluded the data of participants for whom more than 3 blocks were removed.
Statistical analysis
In order to explore the effect of MPH based on ADHD-RS-IV-J scores, we compared the scores (inattention, hyperactivity/impulsivity and total) for before and one month after starting oral administration of MPH. We performed paired t-tests (two tails) with an alpha level set at 0.05.
We performed statistical analyses in a channelwise manner on oxy-Hb signals. For both groups, the following contrasts were generated: (1) firstday pre-medication contrast: target vs. baseline contrast (either PLA or MPH administration) for the first day exclusively; (2) post-medication contrasts (specifically, post-placebo and post-MPH contrasts): target vs. baseline contrast for the post-PLA and post-MPH conditions; (3) intramedication contrasts: difference between post-and pre-medication contrasts for each medication (i.e., intra-PLA and intra-MPH contrasts); and (4) intermedication contrast: difference between intra-MPH and intra-placebo contrasts.
We previously reported that right IFG/MFG activation in ADHD children was acutely normalized after administration of MPH [36, 40, 43] . Thus, we set the right CH10, located at the right IFG/MFG, as a region-of-interest (ROI) for the rest of the study. For the ROI, we performed paired t-tests (two tails) on target vs. baseline contrasts with an alpha level set at 0.05.
To screen the neuropharmacological effects of MPH, we performed comparisons between ADHD with ASD and ADHD without ASD for 
Research Yukifumi Monden
the following three contrasts for the right CH10: (1) post-MPH, (2) intra-MPH, and (3) intermedication. We performed two sample t-tests (two-tails) on these contrasts with an alpha level set at 0.05.
Results
Questionnaire results
The results for the ADHD-RS-IV-J are summarized in Table 3 . The ADHD-RS-IV-J scores 1 month after starting oral MPH were significantly lower than those before starting medication for ADHD both with and without ASD.
fNIRS examination of go/no-go task and MPH effects in ADHD without ASD
We examined oxy-Hb signal changes in the right CH10 for ADHD without ASD in the following contrasts: (1) first-day pre-medication, (2) postmedication, (3) intra-medication, and (4) intermedication. We found no significant activation in the right CH10 during the go/no-go task period of the first-day pre-medicated (paired t-test, p>0.05, Cohen's d=0.35), but significant activation in the post-MPH conditions (paired t-test, p<0.05, Cohen's d=0.87, Table 4, Figure 2 ).
Effects of medications were examined between pre-MPH/PLA and post-MPH/PLA. We observed no significant change in oxy-Hb signal for pre-MPH/PLA and post-MPH/PLA (paired t-test, p>0.05, intra-PLA: Cohen's d=0.06, intra-MPH: Cohen's d=0.37, Table 4 ).
Finally, we tested whether there was an MPHinduced, but not PLA-induced activation. In the inter-medication contrast, the right CH10 was found to have no significant difference (paired t-test, p>0.05, Cohen's d=0.15, Table 4 ).
fNIRS examination of go/no-go task and MPH effects in ADHD with ASD
We examined oxy-Hb signal changes in the right CH10 for ADHD with ASD in the following contrasts: (1) first-day pre-medication, (2) postmedication, (3) intra-medication, and (4) intermedication.
We found marginally significant activation in the right CH10 during the go/no-go task period of the first-day pre-medicated and post-PLA contrast, but a moderate effect size was obtained (paired t-test, p>0.05, first-day pre-medication: Cohen's d=0.60, post-PLA: Cohen's d=0.51, Table 4 , Figure 2 ).
Effects of medications were examined between pre-MPH/PLA and post-MPH/PLA. We observed no significant change in oxy-Hb signal for pre-MPH/PLA and post-MPH/PLA (paired t-test, p>0.05, intra-PLA: Cohen's d=0.28, intra-MPH: Cohen's d=-0.43, Table 4 ). Finally, we tested whether there was an MPHinduced, but not PLA-induced activation. In the inter-medication contrast, the right CH10 was found to have insignificant difference (paired t-test, p>0.05, Cohen's d=0.15, Table 4 ).
Neuropharmacological effect of MPH comparison between ADHD with ASD and without ASD
Comparison between oxy-Hb signals of the ADHD patients with ASD and those without ASD in post-MPH and intra-MPH conditions revealed significant activation of oxy-Hb signal in the right CH10 in the patients without ASD (independent two-sample t-test, p<0.05, post-MPH: Cohen's d=1.16, intra-MPH: Cohen's d=0.86, Table 5 ). In the inter-medication contrast, there was no statistical difference between groups, but a moderate effect size was obtained (independent two-sample t-test, p>0.05, Cohen's d=0.64, Table 5 ).
Discussion
Overview
The current study aimed to explore the neural substrate of MPH effects on inhibition control in medication-naïve ADHD (with ASD (n=11) and without ASD (n=21)) school-aged children using fNIRS. We examined cortical activation in the ROI (right IFG/MFG), where we have consistently found significant activation during go/no-go task periods in control subjects [40, 44] . In the ADHD without ASD group, MPH medication led to increased right IFG/MFG activation. Conversely, in the ADHD with ASD group, MPH medication resulted in decreased right IFG/MFG activation. Finally, in both groups, there was placebo-induced activation in the IFG/MFG, and thus activation in the intermedication (intra-MPH vs intra-PLA) contrast did not reach a significant level.
Placebo effect in medication-naïve ADHD
We examined the placebo effect for several contrasts. At the right CH10, located in the IFG/MFG, oxy-Hb signal during the go/no-go task period was significantly higher than that of the baseline period for ADHD without ASD subjects, and marginally significant in ADHD with ASD in post-PLA conditions. In addition, due to the placebo effect, MPH medication effects on ADHD without ASD exemplified in the inter-medication contrast failed to reach significance. These results suggest that regardless of MPH-induced activation, a non-negligible placebo effect was present, inducing activation in medication-naïve ADHD children both with and without ASD.
The placebo effect was not observed in our past study [40] , which employed the same protocol, including the go/no-go paradigm, double-blind, placebo-controlled and crossover designs for MPH effect. However, participants in the present study were all medication-naïve, while nine out of sixteen were not naïve in the previous study.
In general, more than 50% of clinical trial studies for new psychiatric medications have demonstrated statistical superiority for a placebo over the real medication [68, 69] . It has been suggested that placebo response has increased because of the heightened expectations of patients and researchers for medication effects [70, 71] . Therefore, the placebo-induced neuropharmacological effect found in the present study likely reflects the medicationnaïve ADHD patient's high expectations of MPH. Although investigation into the factors that cause placebo responses is beyond the scope of the current research, we suggest that when exploring neuropharmacological effects using fNIRS, double-blind, placebo-controlled studies should be adopted to account for the impact of the placebo effect.
fNIRS examination of go/no-go task and MPH effects in ADHD without ASD
We found no significant activation in the right IFG/MFG (CH10) during the go/no-go task period in the pre-medicated medication-naïve ADHD participants without ASD, but observed Research Yukifumi Monden significant activation in the post-medicated conditions (Table 4) . These results suggest that the right prefrontal function associated with go/no-go task performance was impaired in medicationnaïve ADHD children without ASD.
The right prefrontal dysfunction and MPHelicited recovery observed using fNIRS is consistent with former studies, with the exception of the placebo-related conditions [43] . Furthermore, these condition-and subject-dependent activation patterns are consistent with the results of previous fMRI studies on ADHD children in general, as well as those on ADHD children without ASD [58, [72] [73] [74] (also see meta analyses by [75] [76] [77] ). Taken together, this suggests that dysfunction of the right IFG/MFG during the initial go/no-go task and the subsequent MPH-induced recovery of right IFG/ MFG activation is robustly applicable to medicationnaïve ADHD children without ASD.
fNIRS examination of go/no-go task and MPH effects in ADHD with ASD
To our surprise, MPH induced opposing neuropharmacological effects in ADHD with and in that without ASD. Specifically, we found marginal activation in the right IFG/MFG during the go/no-go task period in the pre-medicated medication-naïve ADHD subjects with ASD, but we found reduced activation in the postmedicated conditions (Table 4) . Furthermore, comparison between MPH-induced postbaseline ADHD without ASD and ADHD with ASD revealed significantly different oxyHb changes in the right IFG/MFG (CH10). Comparison between intra-MPH in ADHD without ASD and intra-MPH in ADHD with ASD also revealed significantly different changes. Although the number of subjects is too limited to confer a rigid statistical inference, the preset fNIRS study is the first to visualize the distinct neuropharmacological activation patterns between medication-naïve ADHD children with and without comorbid ASD.
Limitations
As discussed above, the current study has demonstrated that MPH-effect assessment in ADHD children using fNIRS can be applicable to medication-naïve ADHD children with and without ASD at elementary school ages. However, several issues need to be addressed before establishing its clinical utility.
First, in the current study, the diagnosis of ADHD with ASD was based on the DSM-5 criteria as in a former fMRI study using ICD-10 [49] . However, the severity and characteristics of ASD comorbidity is better confirmed using a semi-structured assessment (e.g. Autism Diagnostic Observation Schedule, Module 4 [78] and Autism Diagnostic Interview-Revised [79] ). For objective evaluation of ASD traits, semi-structured assessments are needed in the next study.
Second, the present study included a rather small sample size, and further research is needed to increase the sample size of ADHD children with ASD and strengthen the conclusions drawn. Nevertheless, the current study is meaningful in the sense that it reflects the realworld distribution of ADHD children with and without comorbid ASD [80, 81] .
Third, in the current study all of the patients were Japanese children. In order to generalize the different neuroactivation patterns of ADHD with ASD and that without ASD, and the differential neuropharmacological effects of MPH on the IFG/MFG, further racial-ethnic validation studies are needed.
Conclusions
To our knowledge, this is the first comparative fNIRS-based neuropharmacological study between pediatric ADHD with and without comorbid ASD. We demonstrated that MPHinduced neuroactivation patterns in ADHD children with and without ASD are associated with distinct disorder-specific abnormalities. ADHD subjects without ASD exhibited similar neuroactivation in the right IFG/MFG as typically developing children after MPH medication; conversely, ADHD children with ASD had different activation patterns. Therefore, these results suggest that ADHD with ASD is not simply a mixture of two pure disorders, but rather that it has its own distinct neuropathology.
As for clinical utility, in order to ensure successful early diagnosis and treatment of medication-naïve ADHD children without ASD, it is important to establish an objective biomarker to assess the effectiveness of MPH in initial interventions. The current method provides a promising possibility to enable discrimination between responders and non-responders at the earliest possible time. This should further render the effects of MPH treatment observable so as to motivate patient guardians to continue medication. 
